Glycosaminoglycan backbone is not required for the modulation of hemostasis: Effect of different heparin derivatives and non-glycosaminoglycan analogs

Matrix Biology

Volumn 31, Issue 5, 2012, Pages 308-316

  Bouças, Rodrigo I ^a   Jarrouge Bouças, Thais R ^a   Lima, Marcelo A ^a   Trindade, Edvaldo S ^a,b   Moraes, Fabio A ^a   Cavalheiro, Renan P ^a   Tersariol, Ivarne L S ^a,c   Hoppenstead, Debra ^d   Fareed, Jawed ^d   Nader, Helena B ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c UNIVERSIDADE DE MOGI DAS CRUZES   (Brazil)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Antithrombotic drugs; Endothelial cells; Extracellular matrix; Hemorrhagic activity; Smooth muscle cells

Indexed keywords

C3 (DRUG); ENOXAPARIN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; HEPARIN DERIVATIVE; PENTASACCHARIDE; PHOSPHOSULFOMANNAN; SYNTHETIC HEPARIN PENTASACCHARIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTICOAGULATION; ARTICLE; BLEEDING; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HEMOSTASIS; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; VEIN THROMBOSIS;

ANIMALS; ANTICOAGULANTS; BINDING SITES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; FIBRINOLYTIC AGENTS; HEMOSTASIS; HEPARIN; HEPARIN LYASE; MOLECULAR WEIGHT; MYOCYTES, SMOOTH MUSCLE; OLIGOSACCHARIDES; PROTEIN BINDING; PROTEOLYSIS; RABBITS; RATS; SUBSTRATE SPECIFICITY;

EID: 84861684346     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2012.03.001     Document Type: Article

References (68)

1. Andersson L.O., Barrowcliffe T.W., Holmer E., Johnson E.A., Sims G.E. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb. Res. 1976, 9:575-583.
2. Arthur C.K., Isbister J.P., Aspery E.M. The heparin induced thrombosis-thrombocytopenia syndrome (H.I.T.T.S.): a review. Pathology 1985, 17:82-86.
3. Bauer G. Nine years' experience with heparin in acute venous thrombosis. Angiology 1950, 1:161-169.
4. Beijering R.J., ten Cate H., ten Cate J.W. Clinical applications of new antithrombotic agents. Ann. Hematol. 1996, 72:177-183.
5. Berge N., Loganadane L.D., Vassy J., Monnet E., Legrand C., Fauvel-Lafeve F. Adhesion-induced intracellular signalling in endothelial cells depends on the nature of the matrix. Cell Adhes. Commun. 1999, 7:29-41.
6. Best C.H., Cowan C., Maclean D.L. Heparin and the formation of white thrombi. J. Physiol. 1938, 92:20-31.
7. Bianchini P., Nader H., Takahashi H.K., Osima B., Straus A.H., Dietrich C.P. Fractionation and identification of heparin and other acidic mucopolysaccharides by a new discontinuous electrophoretic method. J. Chromatograph. A 1980, 196:455-462.
8. Blossom D.B., Kallen A.J., Patel P.R., Elward A., Robinson L., Gao G., Langer R., Perkins K.M., Jaeger J.L., Kurkjian K.M., Jones M., Schillie S.F., Shehab N., Ketterer D., Venkataraman G., Kishimoto T.K., Shriver Z., McMahon A.W., Austen K.F., Kozlowski S., Srinivasan A., Turabelidze G., Gould C.V., Arduino M.J., Sasisekharan R. Outbreak of adverse reactions associated with contaminated heparin. N. Engl. J. Med. 2008, 359:2674-2684.
9. Bouças R.I., Sampaio L.O., Andrade G.P.V., Lopes C.C., Nascimento F.D., Tersariol I.L.S., Rocha A.O., Nader H.B. Heparin and heparin derivates and their effect on hemostasis. Insights into Carbohydrate Structure and Biological Function 2006, 142-159. H. Verli (Ed.).
10. Capila I., Linhardt R.J. Heparin-protein interactions. Angew. Chem. Int. Ed. 2002, 41:391-412.
11. Colburn P., Buonassisi V. Anti-clotting activity of endothelial cell cultures and heparan sulfate proteoglycans. Biochem. Biophys. Res. Commun. 1982, 104:220-227.
12. Coombe D.R., Kett W.C. Heparan sulfate-protein interactions: therapeutic potential through structure-function insights. Cell. Mol. Life Sci. 2005, 62:410-424.
13. Cruz W.O. The significance of a smooth muscle component in hemostasis. Proc. Soc. Exp. Biol. Med. 1965, 119:876-880.
14. Delacoux F., Fichard A., Geourjon C., Garrone R., Ruggiero F. Molecular features of the collagen V heparin binding site. J. Biol. Chem. 1998, 273:15069-15076.
15. Dietrich C.P., McDuffie N.M., Sampaio L.O. Identification of acidic mucopolysaccharides by agarose gel electrophoresis. J. Chromatogr. 1977, 130:299-304.
16. Dietrich C.P., Tersariol I.L., Toma L., Moraes C.T., Porcionatto M.A., Oliveira F.W., Nader H.B. Structure of heparan sulfate: identification of variable and constant oligosaccharide domains in eight heparan sulfates of different origins. Cell. Mol. Biol. (Noisy-le-Grand) 1998, 44:417-429.
17. Esko J. Essentials of Glycobiology 1999, 441. Cold Spring Harbor Laboratory Press, New York. A. Varki, R. Cummings, J. Esko, H. Freeze, G. Hart, J. Marth (Eds.).
18. Fareed J., Callas D., Hoppensteadt D.A., Lewis B.E., Bick R.L., Walenga J.M. Antithrombin agents as anticoagulants and antithrombotics: implications in drug development. Semin. Hematol. 1999, 36:42-56.
19. Guerrini M., Beccati D., Shriver Z., Naggi A., Viswanathan K., Bisio A., Capila I., Lansing J.C., Guglieri S., Fraser B., Al-Hakim A., Gunay N.S., Zhang Z., Robinson L., Buhse L., Nasr M., Woodcock J., Langer R., Venkataraman G., Linhardt R.J., Casu B., Torri G., Sasisekharan R. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat. Biotechnol. 2008, 26:669-675.
20. Handel T.M., Johnson Z., Crown S.E., Lau E.K., Proudfoot A.E. Regulation of protein function by glycosaminoglycans - as exemplified by chemokines. Annu. Rev. Biochem. 2005, 74:385-410.
21. Hileman R.E., Fromm J.R., Weiler J.M., Linhardt R.J. Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays 1998, 20:156-167.
22. Hirsh J. Heparin induced bleeding. Nouv. Rev. Fr. Hematol. 1984, 26:261-266.
23. Huber R., Carrell R.W. Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry 1989, 28:8951-8966.
24. Johnson Z., Proudfoot A.E., Handel T.M. Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev. 2005, 16:625-636.
25. Jorpes E. Recent trends in anticoagulant therapy of thrombosis. Acta Haematol. 1952, 7:257-270.
26. Kelton J.G., Hirsh J. Bleeding associated with antithrombotic therapy. Semin. Hematol. 1980, 17:259-291.
27. Khachigian L.M., Parish C.R. Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies. Cardiovasc. Drug Rev. 2004, 22:1-6.
28. Kishimoto T.K., Viswanathan K., Ganguly T., Elankumaran S., Smith S., Pelzer K., Lansing J.C., Sriranganathan N., Zhao G., Galcheva-Gargova Z., Al-Hakim A., Bailey G.S., Fraser B., Roy S., Rogers-Cotrone T., Buhse L., Whary M., Fox J., Nasr M., Dal Pan G.J., Shriver Z., Langer R.S., Venkataraman G., Austen K.F., Woodcock J., Sasisekharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. N. Engl. J. Med. 2008, 358:2457-2467.
29. Lane D.A., Caso R. Antithrombin: structure, genomic organization, function and inherited deficiency. Baillieres Clin. Haematol. 1989, 2:961-998.
30. Laux V., Perzborn E., Heitmeier S., von Degenfeld G., Dittrich-Wengenroth E., Buchmuller A., Gerdes C., Misselwitz F. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?. Thromb. Haemost. 2009, 102:892-899.
31. Lima M.A., Rudd T.R., de Farias E.H., Ebner L.F., Gesteira T.F., de Souza L.M., Mendes A., Cordula C.R., Martins J.R., Hoppensteadt D., Fareed J., Sassaki G.L., Yates E.A., Tersariol I.L., Nader H.B. A new approach for heparin standardization: combination of scanning UV spectroscopy, nuclear magnetic resonance and principal component analysis. PLoS One 2011, 6:e15970.
32. Lindahl U., Kusche M., Lidholt K., Oscarsson L.G. Biosynthesis of heparin and heparan sulfate. Ann. N. Y. Acad. Sci. 1989, 556:36-50.
33. Lopes C.C., Toma L., Pinhal M.A., Porcionatto M.A., Sogayar M.C., Dietrich C.P., Nader H.B. EJ-ras oncogene transfection of endothelial cells upregulates the expression of syndecan-4 and downregulates heparan sulfate sulfotransferases and epimerase. Biochimie 2006, 88:1493-1504.
34. Ma Q., Dudas B., Daud A., Iqbal O., Hoppensteadt D., Jeske W., Cornelli U., Lee J., Lorens S., Mervis R., Hanin I., Capila I., Linhardt R., Fareed J. Molecular and biochemical profiling of a heparin-derived oligosaccharide, C3. Thromb. Res. 2002, 105:303-309.
35. Martins J.R., Passerotti C.C., Maciel R.M., Sampaio L.O., Dietrich C.P., Nader H.B. Practical determination of hyaluronan by a new noncompetitive fluorescence-based assay on serum of normal and cirrhotic patients. Anal. Biochem. 2003, 319:65-72.
36. Medeiros G.F., Mendes A., Castro R.A., Bau E.C., Nader H.B., Dietrich C.P. Distribution of sulfated glycosaminoglycans in the animal kingdom: widespread occurrence of heparin-like compounds in invertebrates. Biochim. Biophys. Acta 2000, 1475:287-294.
37. Mulloy B., Linhardt R.J. Order out of complexity-protein structures that interact with heparin. Curr. Opin. Struct. Biol. 2001, 11:623-628.
38. Murray G.D., Best C.H. The use of heparin in thrombosis. Ann. Surg. 1938, 108:163-177.
39. Nader H.B., Buonassisi V., Colburn P., Dietrich C.P. Heparin stimulates the synthesis and modifies the sulfation pattern of heparan sulfate proteoglycan from endothelial cells. J. Cell. Physiol. 1989, 140:305-310.
40. Nader H.B., Dietrich C.P., Buonassisi V., Colburn P. Heparin sequences in the heparan sulfate chains of an endothelial cell proteoglycan. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:3565-3569.
41. Nader H.B., Kobayashi E.Y., Chavante S.F., Tersariol I.L., Castro R.A., Shinjo S.K., Naggi A., Torri G., Casu B., Dietrich C.P. New insights on the specificity of heparin and heparan sulfate lyases from Flavobacterium heparinum revealed by the use of synthetic derivatives of K5 polysaccharide from E. coli and 2-O-desulfated heparin. Glycoconj. J. 1999, 16:265-270.
42. Nader H.B., Lopes C.C., Rocha H.A., Santos E.A., Dietrich C.P. Heparins and heparinoids: occurrence, structure and mechanism of antithrombotic and hemorrhagic activities. Curr. Pharm. Des. 2004, 10:951-966.
43. 13C NMR spectroscopy. J. Biol. Chem. 1990, 265:16807-16813.
44. Nader H.B., Tersariol I.L., Dietrich C.P. Structural requirements of heparin disaccharides responsible for hemorrhage: reversion of the antihemostatic effect by ATP. FASEB J. 1989, 3:2420-2424.
45. Nader H.B., Toma L., Pinhal M.A., Buonassisi V., Colburn P., Dietrich C.P. Effect of heparin and dextran sulfate on the synthesis and structure of heparan sulfate from cultured endothelial cells. Semin. Thromb. Hemost. 1991, 17(Suppl 1):47-56.
46. Norrby K. Low-molecular-weight heparins and angiogenesis. APMIS 2006, 114:79-102.
47. Nozik-Grayck E., Suliman H.B., Piantadosi C.A. Extracellular superoxide dismutase. Int. J. Biochem. Cell Biol. 2005, 37:2466-2471.
48. Olson S.T., Bjork I., Sheffer R., Craig P.A., Shore J.D., Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J. Biol. Chem. 1992, 267:12528-12538.
49. Parish C.R., Freeman C., Brown K.J., Francis D.J., Cowden W.B. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res. 1999, 59:3433-3441.
50. Petitou M., Lormeau J.C., Choay J. A new synthetic pentasaccharide with increased anti-factor Xa activity: possible role for anionic clusters in the interaction of heparin and antithrombin III. Semin. Thromb. Hemost. 1991, 17(Suppl. 2):143-146.
51. Petitou M., van Boeckel C.A. Chemical synthesis of heparin fragments and analogues. Fortschr. Chem. Org. Naturst. 1992, 60:143-210.
52. Pinhal M.A., Santos I.A., Silva I.F., Dietrich C.P., Nader H.B. Minimum fragments of the heparin molecule able to produce the accumulation and change of the sulfation pattern of an antithrombotic heparan sulfate from endothelial cells. Thromb. Haemost. 1995, 74:1169-1174.
53. Powell A.K., Yates E.A., Fernig D.G., Turnbull J.E. Interactions of heparin/heparan sulfate with proteins: appraisal of structural factors and experimental approaches. Glycobiology 2004, 14:17R-30R.
54. Reyers I., Mussoni L., Donati M.B., de Gaetano G. Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb. Res. 1980, 18:669-674.
55. Rocha H.A., Moraes F.A., Trindade E.S., Franco C.R., Torquato R.J., Veiga S.S., Valente A.P., Mourao P.A., Leite E.L., Nader H.B., Dietrich C.P. Structural and hemostatic activities of a sulfated galactofucan from the brown alga Spatoglossum schroederi. An ideal antithrombotic agent?. J. Biol. Chem. 2005, 280:41278-41288.
56. Rudd T.R., Uniewicz K.A., Ori A., Guimond S.E., Skidmore M.A., Gaudesi D., Xu R., Turnbull J.E., Guerrini M., Torri G., Siligardi G., Wilkinson M.C., Fernig D.G., Yates E.A. Comparable stabilisation, structural changes and activities can be induced in FGF by a variety of HS and non-GAG analogues: implications for sequence-activity relationships. Org. Biomol. Chem. 2010, 8:5390-5397.
57. Rudd T.R., Yates E.A. Conformational degeneracy restricts the effective information content of heparan sulfate. Mol. Biosyst. 2010, 6:902-908.
58. Sampaio L.O., Tersariol I.L.S., Lopes C.C., Bouças R.I., Nascimento F.D., Rocha A.O., Nader H.B. Heparins and heparan sulfates. Structure, distribution and protein interactions. Insights into Carbohydrate Structure and Biological Function 2006, 1-24. H. Verli (Ed.).
59. Sasisekharan R., Shriver Z., Venkataraman G., Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat. Rev. 2002, 2:521-528.
60. Sheehan J.P., Wu Q., Tollefsen D.M., Sadler J.E. Mutagenesis of thrombin selectively modulates inhibition by serpins heparin cofactor II and antithrombin III. Interaction with the anion-binding exosite determines heparin cofactor II specificity. J. Biol. Chem. 1993, 268:3639-3645.
61. 2+ exchanger and reduce the cytosolic calcium of smooth muscle cell lines. Requirement of C4-C5 unsaturation and 1--> 4 glycosidic linkage for activity. J. Biol. Chem. 2002, 277:48227-48233.
62. Taylor K.R., Gallo R.L. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J. 2006, 20:9-22.
63. Tersariol I.L., Dietrich C.P., Nader H.B. Interaction of heparin with myosin ATPase: possible involvement with the hemorrhagic activity and a correlation with antithrombin III high affinity-heparin molecules. Thromb. Res. 1992, 68:247-258.
64. Trindade E.S., Oliver C., Jamur M.C., Rocha H.A., Franco C.R., Boucas R.I., Jarrouge T.R., Pinhal M.A., Tersariol I.L., Gouvea T.C., Dietrich C.P., Nader H.B. The binding of heparin to the extracellular matrix of endothelial cells up-regulates the synthesis of an antithrombotic heparan sulfate proteoglycan. J. Cell Physiol. 2008, 217:328-337.
65. Turpie A.G., Gallus A.S., Hoek J.A., Pentasaccharide I. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N. Engl. J. Med. 2001, 344:619-625.
66. Weber P., Zimmermann D.R., Winterhalter K.H., Vaughan L. Tenascin-C binds heparin by its fibronectin type III domain five. J. Biol. Chem. 1995, 270:4619-4623.
67. Yu G., Gunay N.S., Linhardt R.J., Toida T., Fareed J., Hoppensteadt D.A., Shadid H., Ferro V., Li C., Fewings K., Palermo M.C., Podger D. Preparation and anticoagulant activity of the phosphosulfomannan PI-88. Eur. J. Med. Chem. 2002, 37:783-791.
68. Yu G., LeBrun L., Gunay N.S., Hoppensteadt D., Walenga J.M., Fareed J., Linhardt R.J. Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site. Thromb. Res. 2000, 100:549-556.